Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties

Forestier, Christiane; Champs, Christophe de; Vatoux, Catherine; Joly, B

doi:10.1016/s0923-2508(01)01188-3

Cited by 256 publications

(182 citation statements)

References 33 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…Coconnier-Polter et al (2005) have previously reported that the CFS of L. acidophilus could potentially decrease the intracellular ATP content in S. enterica SL1344. Our results are also consistent with those obtained by Forestier et al (2001), who demonstrated (in an in vitro study) that L. casei rhamnosus 35 inhibits the growth of both Gram-positive cocci and Gram-negative bacilli, including P. aeruginosa.…”

Section: Discussionsupporting

confidence: 93%

Lactic acid bacteria protect human intestinal epithelial cells from Staphylococcus aureus and Pseudomonas aeruginosa infections

Affhan¹,

Dachang²,

Xin³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Staphylococcus aureus and Pseudomonas aeruginosa are opportunistic pathogens that cause nosocomial and food-borne infections. They promote intestinal diseases. Gastrointestinal colonization by S. aureus and P. aeruginosa has rarely been researched. These organisms spread to extra gastrointestinal niches, resulting in increasingly progressive infections. Lactic acid bacteria are Gram-positive bacteria that produce lactic acid as the major end-product of carbohydrate fermentation. These bacteria inhibit pathogen colonization and modulate the host immune response. This study aimed to investigate the effects of Lactobacillus acidophilus and Lactobacillus rhamnosus on enteric infections caused by the paradigmatic human pathogens S. aureus ATCC25923 and P. aeruginosa ATCC27853. The effect of whole cells and neutralized cell-free supernatant (CFS) of the lactobacilli on LoVo human carcinoma enterocyte (ATCC CCL-229) infection was analyzed by co-exposure, pre-exposure, and post-exposure studies. Simultaneous application of whole cells and CFS of the lactobacilli significantly eradicated enterocyte infection (P < 0.05); however, this effect was not seen when the whole cells and CFS 17044-17058 (2015) were added after or prior to the infection (P > 0.05). This result could be attributed to interference by extracellular polymeric substances and cell surface hydrophobicity, which resulted in the development of a pathogen that did not form colonies. Furthermore, results of the plate count and LIVE/ DEAD BacLight bacterial viability staining attributed this inhibition to a nonbacteriocin-like substance, which acted independently of organic acid and H 2 O 2 production. Based on these results, the cell-free supernatant derived from lactobacilli was concluded to restrain the development of S. aureus and P. aeruginosa enteric infections.

show abstract

Section: Discussionsupporting

confidence: 93%

Lactic acid bacteria protect human intestinal epithelial cells from Staphylococcus aureus and Pseudomonas aeruginosa infections

Affhan¹,

Dachang²,

Xin³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Lcr35 has been shown to adhere in vitro to the Caco-2 and Int-407 human intestinal cell lines (2). The finding reported here is that Lcr35 can survive in the GI tracts of humans after oral administration, regardless of the dietary and physiological differences among individuals.…”

mentioning

confidence: 51%

“…Its beneficial effects include treatment and prevention of nonorganic diarrhea. We recently showed in vitro that this strain has probiotic activities such as the ability to adhere to intestinal cells and antibacterial activity against several pathogens (2). The aim of the present study was to determine if Lcr35 is able to survive passage through the GI tract and to evaluate the persistence of the strain after discontinuation of its administration.…”

mentioning

confidence: 95%

Persistence of Colonization of Intestinal Mucosa by a Probiotic Strain, Lactobacillus casei subsp. rhamnosus Lcr35, after Oral Consumption

et al. 2003

Self Cite

View full text Add to dashboard Cite

The colonization by the probiotic Lactobacillus casei subsp. rhamnosus Lcr35 of the gastrointestinal tracts of mice and humans was studied. The mice were orally given 10 9 CFU of Lcr35 either once or three times at 24-h intervals. A 16S ribosomal nucleic probe used in hybridization assays detected Lcr35 in the feces of mice for up to 3 days after the feeding, at a level of 10 8 to 10 9 CFU/g of feces. In the human assay, 12 healthy volunteers were enrolled in a randomized trial and ingested Lcr35 at a dosage of 10 8 or 10 10 or 10 12 CFU every day for 7 days. Then, after a 3-week posttreatment period, there was a second intake period similar to the first one. Analysis of fecal samples showed significant increases in the number of lactobacilli during the first intake period, whatever the dose given. The greatest increases were observed in subjects harboring the lowest indigenous population of Lcr35-like bacteria. During the 3-week posttreatment period, the number of CFU slightly decreased over time, and an increase, although not a statistically significant one, was observed during the second test period. These findings suggest that Lcr35 is able to survive within the gastrointestinal tract.Probiotics have been defined as viable microorganisms that have a beneficial effect on health (3). Oral consumption of probiotics has been associated with the prevention or cure of diverse intestinal disorders such as antibiotic-induced diarrheal disease, viral and bacterial diarrhea, lactose intolerance, and inflammatory bowel diseases (10). Much of the early evidence on the actual health effects of probiotics was anecdotal, but in recent years there has been accumulating evidence from rigorous clinical studies that certain well-characterized strains have real health-promoting properties (7). Many mechanisms by which probiotics may protect the host from intestinal disorders have been proposed, including production of inhibitory substances, blockage of adhesion sites, competition for nutrients, and stimulation of immunity. Whatever the underlying mechanism, in order to produce their health effects, the probiotic microorganisms must be able to survive within the gastrointestinal (GI) tract (5) and persist at high levels in the intestine. The minimum effective dose is not precisely known, but the usual recommended oral administration is in excess of 10 9 CFU/day. Several in vitro assays have been used to demonstrate the survival of probiotic strains inside the GI tract, including bile and acid resistance assays (1). However, only human trials can provide evidence of the survival of the probiotic strains in vivo and therefore are required as a basis of a credible claim.Lactobacillus casei subsp. rhamnosus Lcr35 has been successfully exploited commercially as a pharmaceutical product for more than 20 years. Its beneficial effects include treatment and prevention of nonorganic diarrhea. We recently showed in vitro that this strain has probiotic activities such as the ability to adhere to intestinal cells and antibacterial activity a...

show abstract

“…Another is by the secreted nonacidic products as exemplified by L. acidophilus, which inhibited the growth of Salmonella typhimurium, EHEC, enteropathogenic E. coli (EPEC) or Shigella flexneri (2). In the case of L. rhamnosus, notably, a combination of both products was involved (3,5). The second major category is through the interference of parasite adhesion and invasion either directly or indirectly on the receptors.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Lactobacillus rhamnosus on Enterohemorrhagic Escherichia coli Infection of Human Intestinal Cells In Vitro

Hirano

Yoshida

Sugiyama

et al. 2003

Microbiology and Immunology

View full text Add to dashboard Cite

There are many examples of probiotic effects of various lactic bacteria on enteropathogens. In this study, Lactobacillus strains (L. rhamnosus, L. gasseri, L. casei and L. plantarum) were tested in an in vitro model of enterohemorrhagic Escherichia coli (EHEC) infection of a human colon epithelial cell line, C2BBe1. While the adhesion and colonization of EHEC was not affected by any of the lactobacillus strains tested, the internalization of EHEC into the cell line was markedly suppressed by L. rhamnosus, though not by others. Concerning the possible mechanisms, the viabilities of EHEC and host cell were not affected by the presence of L. rhamnosus. Simple competitions at certain receptors were unlikely because the suppressive effect on EHEC internalization was strictly dependent on viable L. rhamnosus and could not be observed with the conditioned medium or killed L. rhamnosus. The fact that L. rhamnosus showed outstanding potential for adhering to the colon epithelial cell line, compared with other strains, suggested that an avid interaction between L. rhamnosus and the host cell might be modulating intra-cellular events responsible for the internalization of EHEC.

show abstract

Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties

Cited by 256 publications

References 33 publications

Lactic acid bacteria protect human intestinal epithelial cells from Staphylococcus aureus and Pseudomonas aeruginosa infections

Lactic acid bacteria protect human intestinal epithelial cells from Staphylococcus aureus and Pseudomonas aeruginosa infections

Persistence of Colonization of Intestinal Mucosa by a Probiotic Strain, Lactobacillus casei subsp. rhamnosus Lcr35, after Oral Consumption

The Effect of Lactobacillus rhamnosus on Enterohemorrhagic Escherichia coli Infection of Human Intestinal Cells In Vitro

Contact Info

Product

Resources

About